TY - JOUR
T1 - Emerging technology in diabetes mellitus
T2 - Glucose monitoring and new insulins
AU - Reynolds, L. Raymond
AU - Karounos, Dennis G.
PY - 2002
Y1 - 2002
N2 - Modern diabetes management requires intensive self-monitoring of blood glucose levels, often coupled with a multicomponent insulin program. Recent advances include alternate site blood glucose testing devices, which facilitate more frequent sampling by individuals with diabetes. Continuous glucose monitoring through interstitial fluid analysis is now available and appears to give a more representative picture of the glycemic variations typical for type 1 diabetes. Recombinant DNA technology has led to the development of new insulin analogs that provide more physiologic insulin delivery. Inhaled and oral insulin formulations may replace multiple injections in future insulin therapy regimens.
AB - Modern diabetes management requires intensive self-monitoring of blood glucose levels, often coupled with a multicomponent insulin program. Recent advances include alternate site blood glucose testing devices, which facilitate more frequent sampling by individuals with diabetes. Continuous glucose monitoring through interstitial fluid analysis is now available and appears to give a more representative picture of the glycemic variations typical for type 1 diabetes. Recombinant DNA technology has led to the development of new insulin analogs that provide more physiologic insulin delivery. Inhaled and oral insulin formulations may replace multiple injections in future insulin therapy regimens.
UR - http://www.scopus.com/inward/record.url?scp=0036340779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036340779&partnerID=8YFLogxK
U2 - 10.1097/00007611-200208000-00024
DO - 10.1097/00007611-200208000-00024
M3 - Review article
C2 - 12190231
AN - SCOPUS:0036340779
SN - 0038-4348
VL - 95
SP - 914
EP - 918
JO - Southern Medical Journal
JF - Southern Medical Journal
IS - 8
ER -